CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities
Net Income (Loss) Attributable to Parent	$ (93,252)	$ (72,201)
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Credit loss expense	1,041	1,156
Depreciation and amortization	20,227	11,898
Amortization of financing costs charged to interest expense	790	448
Accretion of debt discount and non-cash interest expense	0	4,680
Amortization of right-of-use assets	2,939	2,354
Stock-based compensation expense	26,427	20,585
Goodwill impairment	83,149	0
Change in fair value of contingent consideration	(68,018)	1,480
Other non-cash (income) expense, net	6,087	(279)
Increase (Decrease) in Income Taxes	(1,446)	0
Deferred implementation costs	0	1,612
Change in operating assets and liabilities:
Accounts receivable	19,663	10,209
Prepaid expenses and other assets	(1,885)	(1,896)
Accounts payable	(1,821)	2,021
Increase (Decrease) in Accrued Liabilities	(5,770)	2,021
Partner Share liability	(4,821)	(8,768)
Consumer Incentive liability	(9,679)	(2,830)
Net cash used in operating activities	(26,369)	(27,510)
Investing activities
Acquisition of property and equipment	(889)	(1,790)
Acquisition of patents	(57)	(58)
Capitalized software development costs	(6,083)	(4,431)
Business acquisition, net of cash acquired	(2,274)	(494,131)
Net cash used in investing activities	(9,303)	(500,410)
Financing activities
Principal payments of debt	(21)	(11)
Proceeds from issuance of common stock	393	485,690
Payments of Stock Issuance Costs	0	(190)
Payments for Repurchase of Common Stock	40,000	0
Debt issuance costs	(174)	(86)
Net cash received from (used in) financing activities	(39,802)	485,403
Payments for Repurchase of Common Stock	40,000	0
Effect of exchange rates on cash, cash equivalents and restricted cash	(969)	(118)
Net decrease in cash, cash equivalents and restricted cash	(76,443)	(42,635)
Cash, cash equivalents, and restricted cash — Beginning of period	233,562	293,349
Cash, cash equivalents, and restricted cash — End of period	157,119	250,714
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet:
Cash and cash equivalents	157,038	250,603
Restricted cash	81	111
Total cash, cash equivalents and restricted cash — End of period	157,119	250,714
Supplemental schedule of non-cash investing and financing activities:
Cash paid for interest	1,188	1,139
Common stock purchase consideration for the acquisition of Dosh	0	117,354
Amounts accrued for property and equipment and capitalized software development costs	$ 0	$ 390